US, 5/11:In a big development, trial of Pfizer Inc’s experimental antiviral pill for Covid-19 was stopped early after the drug was shown to cut by 89% the chances of hospitalization or death for adults at risk of developing severe disease, the company said on Friday.
The results appear to surpass those seen with Merck & Co Inc’s pill molnupiravir, which was shown last month to halve the likelihood of dying or being hospitalized for Covid-19 patients also at high risk of serious illness.
Full trial data is not yet available from either company.
Comments are closed.